What has changed for a sore knee?

What do the newer knee studies tell me?

A large knee study tested several office procedures. People in each group reported some pain relief. Yet no tested choice clearly beat the steroid medicine. That doesn't mean nobody felt better. It means the study found no clear winner.

The products aren't prepared the same way. One began with marrow taken from the pelvis. Another used body fat that had been broken up or separated. A third used tissue supplied by another person. A result for one can't prove the others work alike.

Smaller studies have found some gains. They haven't removed the doubt. Newer care isn't always better care.

Why can soreness improve for a while?

Joint soreness can rise and fall on its own. Your activity won't stay equal every week. Rest, exercise and extra attention may change how you feel. Hope can't be separated from every pain report.

A useful study compares people given different care. In this study, some got steroid medicine. Others got one of the newer joint products. Researchers then checked whether any group improved more. None clearly did.

You'd still care about any relief. But a better month alone can't show which part helped. Ask how a clinic knows its product caused the change.

What hasn't changed about my choices?

Exercise still has broad support for sore joints. Stronger muscles can share more of the load. Weight loss may help when weight adds strain. A cane or brace might make movement easier. You don't need perfect comfort before gentle work begins.

Office procedures have costs and limits. Regenerative treatments are the clinic term for care using your blood, marrow or fat. A medical provider, the person giving your care, prepares the material near the sore joint. These choices aim for relief without surgery, but results aren't promised.

Surgery may fit better when wear is severe. Don't start with novelty; start with your joint's needs.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. On 27 September 2024 the Ninth Circuit held in United States v. California Stem Cell Treatment Center that stromal vascular fraction produced by enzymatically digesting a patient's own fat IS a drug under the Federal Food, Drug, and Cosmetic Act, and that the same surgical procedure exception does not apply because the removed fat and the implanted SVF are not the same thing. The district court's ruling for the clinics was reversed.

   United States Court of Appeals for the Ninth Circuit — United States v. California Stem Cell Treatment Center, Inc., No. 22-56014 (9th Cir. Sept. 27, 2024). , 2024.

3. On 18 December 2024 FDA approved RYONCIL (remestemcel-L-rknd), the first mesenchymal stromal cell therapy ever approved in the United States - for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months and older, given as eight intravenous infusions. It is not an orthopedic product and does not make any joint injection approved.

   US Food and Drug Administration — FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease. , 2024.

4. In orders issued 26 December 2024 and announced 8 January 2025, a federal court permanently banned the co-founders of the Stem Cell Institute of America and their companies from marketing any regenerative medicine treatment, and ordered $5,155,146 in refunds and civil penalties. The court found on summary judgment that they published false and misleading advertisements about the efficacy and approval of stem cell injections for osteoarthritis, neuropathy and joint pain; their clinic charged up to $5,000 per injection and the customers were almost exclusively elderly and disabled people.

   US Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. , 2025.

5. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample.

   Cao M, et al. — Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2025. DOI: 10.1186/s13287-025-04252-2.

6. A 2025 systematic review and meta-analysis of 6 randomized trials found microfragmented adipose tissue and PRP both reached the minimal clinically important difference on most outcomes to 12 months, with no clear superiority of the fat-derived preparation despite its higher price.

   Park YB, et al. — Microfragmented Adipose Tissue as an Alternative to Platelet-Rich Plasma for Intra-articular Injection in Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Sports Med, 2025. DOI: 10.1177/03635465251337759.

7. A 2025 randomized trial of 66 knee osteoarthritis patients compared a single adipose stromal vascular fraction injection, conventional rehabilitation alone, and the two combined over 12 months - a design that treats exercise-based rehabilitation as a genuine comparator rather than an afterthought.

   Lu J, et al. — Intraarticular injection of the stromal vascular fraction for the treatment of knee osteoarthritis a prospective randomized controlled clinical trial. Sci Rep, 2025. DOI: 10.1038/s41598-025-09398-w.

8. A double-blind placebo-controlled trial of allogeneic culture-expanded adipose MSCs in stage III knee osteoarthritis kept blinding for 12 months and followed the treatment arm to 60 months, reporting only mild transient adverse events - but only 29 subjects completed, 8 of them in the placebo arm.

   Jafar H, et al. — Intra-articular allogeneic adipose-derived mesenchymal stromal cell injections for stage III knee osteoarthritis: a double-blind placebo-controlled trial with 60-month follow-up. Stem Cells Transl Med, 2026. DOI: 10.1093/stcltm/szag018.